Alterity Therapeutics
CompanyAustraliaFounded 1997
Alterity Therapeutics develops one asset, in phase 3 (ATH434 in Parkinson's disease). Mostly small molecule acting on Oxidative stress and ROS signalling and proteostasis; based in Australia, founded in 1997.
- 1
- Asset
- Furthest stage
- Phase 3
- Raised
- A$4.2m
- 2
- Trials
- 1
- Signal
Pipeline
1Chelates and redistributes labile iron to prevent iron-mediated alpha-synuclein aggregation and oxidative damage.
Phase 3, Small molecule, Oxidative stress and ROS signalling, Proteostasis, Parkinson's disease, multiple system atrophy (Phase 2)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Funding rounds and grants1
- People2
- Signals1
- Similar companies6